A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting
HER2 Positive Early or Locally Advanced Breast Cancer
DRUG: Herceptin (trastuzuamb)|DRUG: SB3 (proposed trastuzumab biosimilar)
The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour, Week 24
Total Pathological Complete Response (tpCR) Rate, Week 24|Overall Clinical Response Rate (ORR), Week 24|Event-free Survival (EFS), 1 month after last dose of investigational product|Overall Survival (OS), 1 month after the last administration of investigational product
A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting